SCHEMBL5010265

SCHEMBL5010265

CCOC(=O)Nc1cccc(-c2ccc3c(C)c(C(=O)c4ccc(Cl)cc4Cl)oc3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
NPC1 O15118 3/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 2/20 0.42
RAB9A P51151 2/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MCL1 Q07820 1/20 0.41
TP53 P04637 2/20 0.41
LMNA P02545 2/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
PPARG P37231 1/20 0.39
HIF1A Q16665 1/20 0.39
F2R P25116 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5010939 0.92 MCL1 (0.43) ALDH1A1NPC1RAB9ASMN1; SMN2MCL1
SCHEMBL3557513 0.89 MCL1 (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2MCL1
SCHEMBL5013982 0.86 SMN1; SMN2 (0.43) KDM4ESMN1; SMN2MCL1PPARGHIF1A
SCHEMBL5010251 0.85 MCL1 (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2MCL1
SCHEMBL3558055 0.85 MCL1 (0.42) NPC1RAB9ASMN1; SMN2MCL1TP53
SCHEMBL3553767 0.85 BTK (0.43) ALDH1A1MCL1HTT
SCHEMBL3560389 0.84 MCL1 (0.52) ALDH1A1NPC1HSD17B10RAB9AHPGD
SCHEMBL3553532 0.83 MCL1 (0.43) MCL1MAPTHIF1A
SCHEMBL3102308 0.82 MCL1 (0.50) NPC1HSD17B10RAB9AHPGDSMN1; SMN2
SCHEMBL3556744 0.81 MCL1 (0.47) ALDH1A1NPC1HSD17B10RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7420066-B2 Benzofuran derivatives useful for treating hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2008-09-02 US disclosed
US-20060194816-A1 Benzofuran derivatives useful for treating hyper-proliferative disorders BAER PHAMACEUTICALS CORPORATION (US) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194816-A1 Benzofuran derivatives useful for treating hyper-proliferative disorders MKI67, PCNA, CCNI ALDH1A1 328/4885NPC1 1772/4885HSD17B10 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.